Inozyme Pharma, Inc. (INZY)
NASDAQ
Market Cap
$273.4M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
57 of 809
Rank in Industry
46 of 445
Largest Insider Buys in Sector
INZY Stock Price History Chart
INZY Stock Performance
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Insider Activity of Inozyme Pharma, Inc.
Over the last 12 months, insiders at Inozyme Pharma, Inc. have bought $8M and sold $52,210 worth of Inozyme Pharma, Inc. stock.
On average, over the past 5 years, insiders at Inozyme Pharma, Inc. have bought $36.06M and sold $3.96M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hopfner Robert Lorne (director) — $12M. Pivotal bioVenture Partners Fund I, L.P. (director) — $4M.
The last purchase of 833,333 shares for transaction amount of $4M was made by Pivotal bioVenture Partners Fund I, L.P. (director) on 2023‑08‑01.
List of Insider Buy and Sell Transactions, Inozyme Pharma, Inc.
| 2024-04-02 | Sale | Treco Douglas A | CEO | 7,523 0.0122% | $6.94 | $52,210 | -32.73% | |
| 2023-08-01 | Pivotal bioVenture Partners Fund I, L.P. | director | 833,333 1.4418% | $4.80 | $4M | -8.17% | ||
| 2023-08-01 | Hopfner Robert Lorne | director | 833,333 1.4418% | $4.80 | $4M | -8.17% | ||
| 2023-05-12 | Hopfner Robert Lorne | director | 228,702 0.5377% | $6.25 | $1.43M | -20.56% | ||
| 2023-05-11 | Hopfner Robert Lorne | director | 219,230 0.5045% | $6.48 | $1.42M | -24.92% | ||
| 2023-03-29 | Hopfner Robert Lorne | director | 344,592 0.761% | $4.54 | $1.56M | +7.66% | ||
| 2023-03-28 | Hopfner Robert Lorne | director | 156,766 0.3414% | $4.16 | $652,335 | +14.87% | ||
| 2023-03-27 | Hopfner Robert Lorne | director | 51,074 0.1167% | $3.70 | $188,729 | +35.68% | ||
| 2022-12-15 | Bjarke Henric Bjorn | SVP, COO | 21,500 0.0569% | $1.39 | $29,885 | +205.94% | ||
| 2022-04-19 | ENRIGHT PATRICK G | 1.35M 2.811% | $3.69 | $5M | -33.04% | |||
| 2022-04-19 | Pivotal bioVenture Partners Fund I U.G.P., Ltd | 1.07M 2.2197% | $3.69 | $3.95M | -33.04% | |||
| 2022-04-19 | Hopfner Robert Lorne | 1.07M 2.2197% | $3.69 | $3.95M | -33.04% | |||
| 2022-04-19 | Bolte Axel | Chief Executive Officer | 67,750 0.1405% | $3.69 | $249,998 | -33.04% | ||
| 2022-04-19 | Bjarke Henric Bjorn | SVP, COO | 27,100 0.0562% | $3.69 | $99,999 | -33.04% | ||
| 2022-04-19 | Subramanian Sanjay | SVP, CFO | 27,100 0.0562% | $3.69 | $99,999 | -33.04% | ||
| 2021-06-24 | Sale | Bolte Axel | Chief Executive Officer | 66,788 <0.0001% | $0.00 | $7 | -57.67% | |
| 2021-01-28 | Sale | Novo Holdings A/S | 10 percent owner | 375,000 1.469% | $21.00 | $7.88M | -30.07% | |
| 2020-07-28 | Longitude Capital Partners III, LLC | 10 percent owner | 1.25M 6.0841% | $16.00 | $20M | +19.03% | ||
| 2020-07-28 | Novo Holdings A/S | 10 percent owner | 375,000 1.8252% | $16.00 | $6M | +19.03% | ||
| 2020-07-28 | Sonsini Peter W. | 10 percent owner | 250,000 1.2168% | $16.00 | $4M | +19.03% |
Insider Historical Profitability
11.33%
| Hopfner Robert Lorne | director | 2923110 4.733% | $4.42 | 8 | 0 | <0.0001% |
| Pivotal bioVenture Partners Fund I, L.P. | director | 2923110 4.733% | $4.42 | 2 | 0 | +19.03% |
| Treco Douglas A | CEO | 20665 0.0335% | $4.42 | 0 | 1 | |
| ENRIGHT PATRICK G | 4174379 6.759% | $4.42 | 1 | 0 | <0.0001% | |
| Longitude Capital Partners III, LLC | 10 percent owner | 2819379 4.565% | $4.42 | 1 | 0 | +19.03% |
| Pivotal bioVenture Partners Fund I U.G.P., Ltd | 2661154 4.3088% | $4.42 | 1 | 0 | <0.0001% | |
| BASKETT FOREST | 10 percent owner | 2437689 3.947% | $4.42 | 1 | 0 | +19.03% |
| MAKOWER JOSHUA | 10 percent owner | 2437689 3.947% | $4.42 | 1 | 0 | +19.03% |
| SANDELL SCOTT D | 10 percent owner | 2437689 3.947% | $4.42 | 1 | 0 | +19.03% |
| Sonsini Peter W. | 10 percent owner | 2437689 3.947% | $4.42 | 1 | 0 | +19.03% |
| Makhzoumi Mohamad | 10 percent owner | 2437689 3.947% | $4.42 | 1 | 0 | +19.03% |
| Florence Anthony A. Jr. | 10 percent owner | 2437689 3.947% | $4.42 | 1 | 0 | +19.03% |
| New Enterprise Associates 15, L.P. | 10 percent owner | 2437689 3.947% | $4.42 | 1 | 0 | +19.03% |
| Novo Holdings A/S | 10 percent owner | 2194379 3.553% | $4.42 | 1 | 1 | +19.03% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2028308 3.2841% | $4.42 | 1 | 0 | +19.03% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 2003653 3.2442% | $4.42 | 1 | 0 | +19.03% |
| Rock Springs Capital Management LP | 10 percent owner | 1067884 1.7291% | $4.42 | 1 | 0 | +19.03% |
| Sanofi | 10 percent owner | 520125 0.8422% | $4.42 | 1 | 0 | +19.03% |
| Bolte Axel | Chief Executive Officer | 258575 0.4187% | $4.42 | 1 | 1 | <0.0001% |
| Bjarke Henric Bjorn | SVP, COO | 105441 0.1707% | $4.42 | 2 | 0 | +86.45% |
| Subramanian Sanjay | SVP, CFO | 27100 0.0439% | $4.42 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Adage Capital Partners Gp L L C | $40.82M | 8.62 | 5.33M | -3.77% | -$1.6M | 0.07 | |
| Pivotal Bioventure Partners Investment Advisor Llc | $34.43M | 7.27 | 4.49M | 0% | +$0 | 25.25 | |
| Sofinnova | $32.79M | 6.92 | 4.28M | 0% | +$0 | 0.07 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $28.2M | 5.95 | 3.68M | 0% | +$0 | 0.72 | |
| Eventide Asset Management | $24.36M | 5.14 | 3.18M | 0% | +$0 | 0.38 | |
| BlackRock | $23.66M | 4.99 | 3.09M | +1.52% | +$354,834.18 | <0.01 | |
| Samlyn Capital, LLC | $22.31M | 4.71 | 2.91M | -13.63% | -$3.52M | 0.39 | |
| Affinity Asset Advisors | $20.24M | 4.27 | 2.64M | +40.13% | +$5.8M | 3.6 | |
| Nea Management Company Llc | $18.67M | 3.94 | 2.44M | 0% | +$0 | 0.21 | |
| The Vanguard Group | $18.53M | 3.91 | 2.42M | +1.43% | +$260,424.68 | <0.0001 | |
| Fidelity Investments | $15.07M | 3.18 | 1.97M | -13.42% | -$2.34M | <0.01 | |
| Samsara Biocapital Llc | $11.97M | 2.53 | 1.56M | 0% | +$0 | 1.87 | |
| Sphera Fund | $10.52M | 2.22 | 1.37M | -12.16% | -$1.46M | 1.74 | |
| Blue Owl Capital Holdings Lp | $9.73M | 2.05 | 1.27M | 0% | +$0 | 1.83 | |
| Geode Capital Management | $8.18M | 1.73 | 1.07M | +3.37% | +$266,312.61 | <0.01 | |
| Woodline Partners LP | $6.8M | 1.44 | 888,067 | +196.02% | +$4.5M | 0.06 | |
| State Street | $6.75M | 1.42 | 880,639 | +17.96% | +$1.03M | <0.0001 | |
| Millennium Management LLC | $5.39M | 1.14 | 703,606 | -22.8% | -$1.59M | <0.01 | |
| Kennedy Capital Management Inc | $3.35M | 0.71 | 437,657 | +52.21% | +$1.15M | 0.07 | |
| Northern Trust | $3.22M | 0.68 | 419,879 | -1.14% | -$36,982.49 | <0.01 | |
| Goldman Sachs | $3.14M | 0.66 | 409,923 | +12.81% | +$356,580.64 | <0.01 | |
| Laurion Capital Management LP | $3.08M | 0.65 | 402,197 | -27.84% | -$1.19M | 0.09 | |
| Wellington Management Company | $1.87M | 0.4 | 244,200 | New | +$1.87M | <0.0001 | |
| Parkman Healthcare Partners Llc | $1.71M | 0.36 | 222,943 | +4.95% | +$80,514.24 | 0.21 | |
| Overbrook Management Corp | $1.68M | 0.36 | 219,326 | 0% | +$0 | 0.45 | |
| Ubs Oconnor Llc | $1.4M | 0.3 | 183,218 | -25.2% | -$472,698.64 | 0.12 | |
| Dimensional Fund Advisors | $1.34M | 0.28 | 174,647 | +174.24% | +$849,968.91 | <0.0001 | |
| Renaissance Technologies | $1.33M | 0.28 | 173,700 | -20.5% | -$343,286.13 | <0.01 | |
| BNY Mellon | $1.26M | 0.27 | 164,432 | +4.06% | +$49,154.29 | <0.0001 | |
| Nuveen | $1.23M | 0.26 | 160,879 | 0% | +$0 | <0.0001 | |
| Gsa Capital Partners Llp | $1M | 0.21 | 131,098 | -21.5% | -$274,982.26 | 0.08 | |
| Charles Schwab | $969,258.00 | 0.21 | 126,535 | +4.02% | +$37,419.10 | <0.0001 | |
| Morgan Stanley | $951,724.00 | 0.2 | 124,246 | +7.59% | +$67,147.54 | <0.0001 | |
| Citadel Advisors LLC | $710,220.00 | 0.15 | 92,718 | -41.86% | -$511,266.79 | <0.0001 | |
| Schonfeld Group | $572,968.00 | 0.12 | 74,800 | -31.19% | -$259,674.00 | <0.01 | |
| RhumbLine Advisers | $483,619.00 | 0.1 | 63,137 | +4.71% | +$21,776.91 | <0.0001 | |
| Prelude Capital | $478,329.00 | 0.1 | 62,445 | New | +$478,329.00 | 0.03 | |
| JPMorgan Chase | $471,680.00 | 0.1 | 61,577 | +79.34% | +$208,666.14 | <0.0001 | |
| Bank of America | $458,788.00 | 0.1 | 59,894 | -18.73% | -$105,738.63 | <0.0001 | |
| American Century Investments | $393,931.00 | 0.08 | 51,427 | +79.22% | +$174,127.20 | <0.0001 | |
| UBS | $367,374.00 | 0.08 | 47,960 | +3.79% | +$13,428.00 | <0.0001 | |
| Alps Advisors Inc | $333,670.00 | 0.07 | 43,560 | +3.19% | +$10,302.71 | <0.01 | |
| Two Sigma Advisers LP | $316,358.00 | 0.07 | 41,300 | -41.58% | -$225,204.00 | <0.01 | |
| Barclays | $282,000.00 | 0.06 | 36,909 | -46.6% | -$246,135.90 | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $266,813.00 | 0.06 | 34,832 | New | +$266,813.00 | <0.01 | |
| Balyasny Asset Management Llc | $240,371.00 | 0.05 | 31,380 | New | +$240,371.00 | <0.01 | |
| Susquehanna International Group | $230,980.00 | 0.05 | 30,154 | -30.93% | -$103,433.14 | <0.0001 | |
| Two Sigma | $228,980.00 | 0.05 | 29,893 | -44.33% | -$182,361.32 | <0.0001 | |
| Jane Street Capital | $222,791.00 | 0.05 | 29,085 | -43.42% | -$170,963.46 | <0.0001 | |
| AQR Capital | $212,305.00 | 0.05 | 27,716 | -39.63% | -$139,389.31 | <0.0001 |